These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16165921)

  • 1. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.
    Essand M
    Acta Oncol; 2005; 44(6):610-27. PubMed ID: 16165921
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of experimental therapeutics for prostate cancer.
    Moon C; Park JC; Chae YK; Yun JH; Kim S
    Cancer Lett; 2008 Aug; 266(2):116-34. PubMed ID: 18440696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of prostate cancer.
    Doehn C
    Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene therapy for prostate cancer.
    Hrouda D; Perry M; Dalgleish AG
    Semin Oncol; 1999 Aug; 26(4):455-71. PubMed ID: 10482188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
    Minev BR; Guo F; Gueorguieva I; Kaiser HE
    In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenoviral strategies for the gene therapy of cancer.
    Relph KL; Harrington KJ; Pandha H
    Semin Oncol; 2005 Dec; 32(6):573-82. PubMed ID: 16338423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
    Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
    Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological principles and clinical development of prostate cancer gene therapy.
    Sanda MG
    Semin Urol Oncol; 1997 Feb; 15(1):43-55. PubMed ID: 9050139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining gene and immunotherapy for prostate cancer.
    Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND
    Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
    Qi SY; Wang M; Xu Y
    Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination.
    Kaufman HL; Divgi CR
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6757-62. PubMed ID: 16203760
    [No Abstract]   [Full Text] [Related]  

  • 20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.